Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.

Importance Extracranial carotid and vertebral artery dissection is an important cause of stroke, particularly in younger individuals. In some but not all observational studies, it has been associated with a high risk of recurrent stroke. Both antiplatelet agents (APs) and anticoagulants (ACs) are used to reduce stroke risk, but whether 1 treatment strategy is more effective is unknown. Objective To determine whether AP or AC therapy is more effective in preventing stroke in cervical dissection and the risk of recurrent stroke in a randomized clinical trial setting. A secondary outcome was to determine the effect on arterial imaging outcomes. Design, Setting and Participants Randomized, prospective, open-label international multicenter parallel design study with central blinded review of both clinical and imaging end points. Recruitment was conducted in 39 stroke and neurology secondary care centers in the United Kingdom and 7 centers in Australia between February 24, 2006, and June 17, 2013. One-year follow-up and analysis was conducted in 2018. Two hundred fifty participants with extracranial carotid and vertebral dissection with symptom onset within the last 7 days were recruited. Follow-up data at 1 year were available for all participants. Interventions Randomization to AP or AC (heparin followed by warfarin) for 3 months, after which the choice of AP and AC agents was decided by the local clinician. Main Outcomes and Measures The primary end point was ipsilateral stroke and death. A planned per protocol (PP) analysis was performed in patients meeting the inclusion criteria following central review of imaging to confirm the diagnosis of dissection. A secondary end point was angiographic recanalization in those with imaging confirmed dissection. Results Two hundred fifty patients were randomized (118 carotid and 132 vertebral), 126 to AP and 124 to AC. Mean (SD) age was 49 (12) years. Mean (SD) time to randomization was 3.65 (1.91) days. The recurrent stroke rate at 1 year was 6 of 250 (2.4%) on ITT analysis and 5 of 197 (2.5%) on PP analysis. There were no significant differences between treatment groups for any outcome. Of the 181 patients with confirmed dissection and complete imaging at baseline and 3 months, there was no difference in the presence of residual narrowing or occlusion between those receiving AP (n = 56 of 92) vs those receiving AC (n = 53 of 89) (P = .97). Conclusions and Relevance During 12 months of follow-up, the number of recurrent strokes was low. There was no difference between treatment groups in outcome events or the rate of recanalization. Trial Registration ISRCTN.com Identifier: CTN44555237.

[1]  P. Touboul,et al.  Time course of symptoms in extracranial carotid artery dissections. A series of 80 patients. , 1995, Stroke.

[2]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[3]  D. Leys,et al.  Cervical-artery dissections: predisposing factors, diagnosis, and outcome , 2009, The Lancet Neurology.

[4]  H. Markus,et al.  Antiplatelets vs anticoagulation for dissection , 2012, Neurology.

[5]  Cervical Artery Dissection in Stroke Study Trial Investigators Antiplatelet Therapy vs. Anticoagulation in Cervical Artery Dissection: Rationale and Design of the Cervical Artery Dissection in Stroke Study (CADISS) , 2007, International journal of stroke : official journal of the International Stroke Society.

[6]  A. Woolfenden,et al.  Cervical Arterial Dissection: Time for a Therapeutic Trial? , 2003, Stroke.

[7]  V. Rousson,et al.  Aspirin vs anticoagulation in carotid artery dissection , 2009, Neurology.

[8]  K. Aho,et al.  Cerebrovascular disease in the community: results of a WHO collaborative study. , 1980, Bulletin of the World Health Organization.

[9]  C. Levi,et al.  Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial , 2015, The Lancet Neurology.

[10]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.